Clinical trials: Hepatic Cirrhosis
Liver Cancer, Hepatocellular Carcinoma
AI Multimodal Model for Liver Cancer Diagnosis and Prognosis
This study aims to develop a comprehensive artificial intelligence model system integrating preoperative multimodal data (CT/MRI imaging, clinical laboratory data, and radiology report text) to achieve two core objectives.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma (Icc)
- Trial name
- AIM-LCAP (NCT07658586)
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Guangxi Medical University
Liver Cirrhosis, Early Allograft Dysfunction
Intraoperative Assessment of Microcirculatory Function Using Vascular Occlusion Test During Liver Transplantation
Early allograft dysfunction (EAD) remains one of the most important complications following orthotopic liver transplantation (OLT).
- Trial name
- NCT07658794
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Ippokrateio General Hospital of Thessaloniki
Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC)
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT).
- Conditions
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
- Trial name
- NCT07678645
- Testing
- Upadacitinib 15 MG
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RenJi Hospital
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients…
- Conditions
- Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
- Trial name
- NAVIGATE (NCT04365868)
- Testing
- belapectin
- Where
- 156 sites in United States, Argentina and 13 more
- Volunteers
- 357 people
- Sponsor
- Galectin Therapeutics Inc.
Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD)
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients
The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD), Liver Fibrosis
- Trial name
- SOPRANO (NCT05699018)
- Testing
- eLIFT
- Where
- 13 sites in France
- Volunteers
- 1,788 people
- Sponsor
- University Hospital, Angers
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Deep Learning for Liver Fibrosis Triage in MASLD Using Longitudinal Electronic Health Records
This study looks at a new computer program called NIMIT-AI (Neural Inference for Metabolic-liver Integrated Trajectories, Artificial Intelligence) that helps doctors find liver scarring early in patients with fatty liver disease.
- Trial name
- NIMIT-AI (NCT07675525)
- Testing
- Longitudinal electronic health record analysis
- Where
- Thailand
- Volunteers
- 1,351 people
- Sponsor
- Siriraj Hospital
Liver Fibroses, Liver Cirrhoses
Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck
Tobacco and alcohol are the two major risk factors for upper respiratory tract cancer (VADS).
- Conditions
- Liver Fibroses, Liver Cirrhoses, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- fibr'HOM (NCT03139058)
- Testing
- Evaluation of the hepatic fibrosis
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Alcohol Dependence, Dependence
Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients
80% of patients with alcohol use disorders (AUD) present cognitive impairments, such as memory and executive functions. These disorders may have repercussions in addiction treatment by altering the patient's adherence to care.
- Conditions
- Alcohol Dependence, Dependence, Cognitive Impairments, Cirrhosis
- Trial name
- CirCo (NCT04490330)
- Testing
- questionnaire
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Obesity, Liver Diseases
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting…
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat
- Trial name
- NCT06138821
- Testing
- ESG + lifestyle modification, Lifestyle modification
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Pichamol Jirapinyo, MD, MPH
Cirrhosis of the Liver, Ascites
Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting Complications and Sarcopenia in Limited Resource Settings
The goal of this observational study is to learn how liver cirrhosis affects the diaphragm, the main muscle used for breathing, in adults.
- Conditions
- Cirrhosis of the Liver, Ascites, Pleural Effusion Disorder, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07667608
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assiut University
Cirrhosis, Liver, Advanced Liver Fibrosis
Erlotinib for Hepatocellular Carcinoma Chemoprevention
This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.
- Trial name
- ECHO-B (NCT04172779)
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase…
- Trial name
- NCT05395481
- Testing
- LY3849891
- Where
- 16 sites in United States, Japan and 1 more
- Volunteers
- 115 people
- Sponsor
- Eli Lilly and Company
Metabolic Dysfunction-associated Fatty Liver Cirrhosis
Fuzheng Huayu Tablets for Metabolic Dysfunction-Associated Fatty Liver Cirrhosis (Compensated): A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study
This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Fuzheng Huayu Tablets in patients with metabolic dysfunction-associated fatty liver cirrhosis…
- Trial name
- NCT07663643
- Testing
- Fuzheng Huayu Tablets
- Volunteers
- 459 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Diabetes Mellitus, Type 2, Metabolic Associated Fatty Liver Disease
Correlation Between Serum Nociceptin and Sympathetic Nerve Activity in Diabetic Patients With MAFLD
This observational study aims to investigate the relationship between serum nociceptin levels and sympathetic nervous system activity in patients with both type 2 diabetes mellitus (T2DM) and metabolic associated fatty liver…
- Trial name
- NCT07663682
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Second Hospital of Shanxi Medical University
Cholestasis
Linerixibat Long-term Safety, and Tolerability Study
This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who…
- Trial name
- LLSAT (NCT04167358)
- Testing
- Linerixibat
- Where
- 94 sites in United States, Argentina and 15 more
- Volunteers
- 242 people
- Sponsor
- GlaxoSmithKline
Fibrosis, Liver
Screening for Chronic Liver Diseases in General Population
Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.
- Trial name
- HEPGEN (NCT06366425)
- Testing
- Blood sample then fibroscan
- Where
- France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Montpellier
Liver Cirrhosis
To Evaluate the Feasibility of Collecting Duodenal Fluid With SIMBA Capsules
In this study, the feasibility to use SIMBA (Small Intestinal MicroBiome Aspiration) capsules to collect small intestinal microbiome and metabolome information will be evaluated in patients with liver cirrhosis.
- Trial name
- CAP (NCT06708832)
- Testing
- SIMBA ingestion
- Where
- Austria
- Volunteers
- 11 people
- Sponsor
- Vanessa Stadlbauer-Koellner, MD
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Heart Failure, Congestive, Renal Failure Acute Chronic
Effect of a Focused Point-of-care Ultrasonography Screening Protocol in Hospitalized Patients
This research project aims to establish a real-time focused ultrasound examination protocol for routine assessment of hospitalized patients, including evaluations of the inferior vena cava (IVC), pericardial effusion…
- Conditions
- Heart Failure, Congestive, Renal Failure Acute Chronic, Liver Cirrhosis, Sepsis
- Trial name
- NCT07656428
- Where
- Taiwan
- Volunteers
- 9,000 people
- Sponsor
- National Taiwan University Hospital
Cholangiocarcinoma, Cirrhosis
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
This phase I trial studies the side effects and the best dose of radiation therapy in treating patients with hepatocellular carcinoma, cholangiocarcinoma, or cancer that has spread from the original (primary) tumor to the liver…
- Conditions
- Cholangiocarcinoma, Cirrhosis, Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT02626312
- Testing
- Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Radiation Therapy
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center